These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39052709)

  • 1. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
    Chong EA; Kumashie KG; Chong ER; Fabrizio J; Gupta A; Svoboda J; Barta SK; Walsh KM; Napier EB; Lundberg RK; Nasta SD; Gerson JN; Landsburg DJ; Gonzalez J; Gaano A; Weirick ME; McAllister CM; Awofolaju M; John GN; Kammerman SC; Novacek J; Pajarillo R; Lundgreen KA; Tanenbaum N; Gouma S; Drapeau EM; Adamski S; D'Andrea K; Pattekar A; Hicks A; Korte S; Sharma H; Herring S; Williams JC; Hamilton JT; Bates P; Hensley SE; Prak ETL; Greenplate AR; Wherry EJ; Schuster SJ; Ruella M; Vella LA
    J Infect Dis; 2024 Jul; 230(1):15-27. PubMed ID: 39052709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
    Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
    Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
    Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
    Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
    [No Abstract]   [Full Text] [Related]  

  • 6. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
    Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
    Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
    Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization.
    Wang J; Guo C; Cai L; Liao C; Yi H; Li Q; Hu H; Deng Q; Lu Y; Guo Z; Chen Z; Lu J
    Front Immunol; 2021; 12():772511. PubMed ID: 34868035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
    J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.